Taiwan Liposome Company, Ltd. - ADRs (TLC) Company Bio
Taiwan Liposome Company, Ltd. is a Taiwan-based company principally engaged in the research and development and commercialization of lipid drug delivery systems. The Company is engaged in the development of special generic drugs, new formulas and new drugs using patents. The Company's therapeutic areas include pain management, eye diseases and cancer. Its anticancer medicine product named Lipo-Dox has been distributed in domestic and Asian markets.
Thinly traded micro cap Taiwan Liposome (TLC) surges 100% premarket on increased volume in reaction to its submission of an Investigational New Drug ((IND)) Application to the Taiwan Food and Drug Administration seeking sign off on a clinical trial of TLC19 Hydroxychloroquine Liposome Inhalation Suspension, an inhaled formulation of the malaria med, for the potential treatment...
Results show that TLC590 demonstrated greater reductions in pain than both placebo and bupivacaine through 168 hours. TLC590 is a non-opioid, proprietary BioSeizer® sustained release formulation of ropivacaine.